Company intelligence
Epsilogen Ltd
Harnessing the power of IgE
Biotechnology
Hammersmith, GB
33 employees
Founded 2016
2 public signals
About Epsilogen Ltd
Epsilogen is a global leader in the development of immunoglobulin (IgE) antibodies to treat cancer. IgE has several key features that make it ideal for the treatment of solid tumours including greater potency, enhanced tumour access and a long tissue half-life. The company's lead programme targets the folate receptor alpha (FR alpha) and an anti-FR alpha IgE antibody is currently in a phase I trial to treat ovarian cancer. This is the world's first IgE therapeutic to enter the clinic.
Verified activity
Signals from Epsilogen Ltd
2 published signals
Presence & Recognition
Epsilogen Ltd participated in the first British BioCycle cycle ride organized by Cancer Research UK, CRUK, Cancer Research Horizons, and British Business Bank in aid of CRUK.
Reported by Epsilogen Ltd
Research & Knowledge
Epsilogen Ltd is working on potential therapeutics for gynaecological cancers including ovarian, cervical, uterine, vaginal, and vulval cancer.
Reported by Epsilogen Ltd